PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
Proso millet-based products (biscuits, couscous, porridge, and extruded snacks) showed a different postprandial blood glucose response compared to refined corn products [PMID:28292202].
In an in vitro fecal incubation model, proso millet altered alpha and beta diversity of human gut microbiota, increasing beneficial genera such as Bifidobacterium and decreasing taxa such as Enterobacteriaceae and Flavonifractor [PMID:40741631].
Extracts demonstrated dose-dependent spasmolytic, bronchodilator, and hypotensive activities in isolated rabbit jejunum, trachea, and aorta [PMID:35360455].
Evidence summary
PubMed sources
- 1.PMID: 34536472 (2021) — Proso-millet starch: Properties, functionality, and applications. · International journal of biological macromolecules
- 2.PMID: 30683860 (2019) — The genome of broomcorn millet. · Nature communications
- 3.PMID: 37372623 (2023) — A Review on Isolation, Characterization, Modification, and Applications of Proso Millet Starch. · Foods (Basel, Switzerland)
- 4.PMID: 28119699 (2016) — Proso Millet (Panicum miliaceum L.) and Its Potential for Cultivation in the Pacific Northwest, U.S.: A Review. · Frontiers in plant science
- 5.PMID: 36176305 (2022) — SNP discovery in proso millet (Panicum miliaceum L.) using low-pass genome sequencing.